ADL BIONATUR SOLUTIONS

Trading sesion


22/10/2021 11:47:42

0.5740

Last price


24.80 mill. €

Capitalisation

2.14

Dif.(%)


1.08

% Year 2021

Last Trade

Date

22/10/2021

Hour

11:47:42

Last

0.5740

Ref.

0.5620

Dif.(%)

2.14

Volume (Shares)

233,123

Turnover (€x1000)

128.6

X
22/10/2021 11:49:10
BidAsk
OrdersVolumePricePriceVolumeOrders
36,8190.55800.57802,9702
120,0000.55600.58005,0001
22,6010.55200.586015,6002
25,1500.55000.58804,9111
12,2950.54600.592015,0001

Security

Security name

ADL BIONATUR SOLUTIONS

Ticker

ADL

ISIN

ES0184980003

NIF

A-11811163

Shares Admitted

44.123.664

Nominal

0,05 Euros

Capital Admitted

2.206.183,20 Euros

Trading

Continuo

Liquidity Provider

AURIGA GLOBAL INVESTORS S.V., S.A.

Registered Advisor

IMPULSA CAPITAL S.L.

Auditor

ERNST & YOUNG S.L.

Address

AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA

Contact

ir@adlbionatur.com

Historical Summary

 20172018201920202021 until 21/10

Capital Admitted (thousands of euros)

2551,9691,9691,9692,206

Shares (x 1,000)

5,09039,38939,38939,38944,124

Period Close Price (euros)

2.98001.67002.04000.55600.5620

Period Last Price (euros)

2.98001.67002.04000.55600.5620

Period High Price (euros)

3.96003.68002.50002.28001.0850

Period Low Price (euros)

1.40001.58001.63000.35000.4330

Capitalisation (thousands of euros)

15,16965,78080,35421,90024,797

Volume (thousands of shares)

9752,7133,69825,81059,231

Turnover (thousands of euros)

2,4796,2357,75916,05944,584

Company Profile

ADL Bionatur is a biotechnology group strategically focused on the ‘One Health’ concept which encompasses human and animal health. Subsidiaries and a global commercial structure devoted to the monetisation of their different high-valued assets. Depending on their field of application, these assets can be categorised as follows: 1) detection / diagnosis, 2) prevention, 3) therapeutic, 4) fermentation ingredients.
 
The Group's main strategy is to foster its commercial network in order to leverage the organic growth of its assets while evaluating opportunities of inorganic growth in the biotechnology field.

Inside Information

Other Relevant Information

Notices

Relevant Facts until 10/05/2020

Significant participations

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.